Urology Journal

Abstract

Purpose: We aimed to compare the effectiveness of intranasal desmopressin and doxazosin treatments
in patients with nocturia and benign prostatic hyperplasia (BPH).
Material and Methods: Thirty one men with BPH and three or more episodes of nocturia were
randomized to receive 2 mg doxazosin at night for two weeks increasing to 4 mg for a further two
weeks versus 20 μg intranasal desmopressin at night. For all patients, number of nocturia, urinary
flow rate, residual urine volume and quality of life score were checked. Outcomes were measured at
two months. The comparison of before and after treatment changes between the groups were done
by student’s t-test.
Results: In doxazosin group, mean number of nocturia were 3.2 ± 0.4 (3-4 times) times per night and
1.2 ± 0.8 (0-3 times) times per night before and after treatment, respectively. In desmopressin group,
mean number of nocturia were 3.4 ± 0.5 (3-4 times) and 1.5 ± 0.6 (1-3 times) times per night before
and after treatment, respectively. In doxazosin group, mean residual urine volumes were 44.3 ± 35.9
ml (range 0-120 ml) and 23.1 ± 18.8 ml (range 0-50 ml) before and after treatment, respectively. In
desmopressin group, mean residual urine volumes were 36.6 ± 32.4 ml (range 0-120 ml) and 14.0 ±
26.9 ml (range 0-90 ml) before and after treatment, respectively. Improvements in number of nocturia,
residual urine volume, quality of life scores and peak urinary flow rates weren’t statistically
significant between two groups, whereas change in international prostate symptom score (IPSS) score
was more significant in doxazosin group.
Conclusion: Intranasal desmopressin, is an effective symptomatic treatment of men with BPH complaining
of nocturia, as well as doxazosin treatment.